Larch Arabinogalactan and gut bacteria

What 2 graded rows on larch arabinogalactan agree on for gut bacteria, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Larch Arabinogalactan page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Larch Arabinogalactan page, with its PubMed record.

Supplement

Larch Arabinogalactan Choose another

2 rows · 50 people

Inconsistent: both rows reported mixed results.

Mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade D, is a crossover trial of 30 people (2021) and reported mixed results.

Each row reported mixed results on its own, so there is no side to compare. The rows enrolled 20 to 30 people and were published from 2001 to 2021.

2 mixed

Grade DGut microbiome and digestive tolerance · Mixed
Crossover RCT · n 30 · 2021 · Healthy adults
15 g/day · 6 weeks per period
Bacteroidetes rose and Firmicutes fell versus placebo, Bifidobacterium tended to rise, and microbiome diversity (alpha-diversity) fell. Bowel habit, stool consistency, GI symptoms, blood chemistry and vital signs did not change.
Row on the Larch Arabinogalactan page · PubMed 34004416 (opens PubMed)
Grade DGut bacteria and stool measures · Mixed
RCT · n 20 · 2001 · Healthy adults (11 men, 9 women)
15 g/day and 30 g/day · Two 3-week periods without washout
Total faecal anaerobes rose at both doses and Lactobacillus rose over 6 weeks; faecal ammonia fell. No change in transit time, bowel frequency, stool weight, short-chain fatty acids, blood lipids or insulin.
Row on the Larch Arabinogalactan page · PubMed 11506055 (opens PubMed)